AbbVie Inc. financial statements show the company's earnings, expenses, and comprehensive income for the three and nine months ended September 30, outlining net earnings, operating expenses, and total assets. Additionally, the statements of equity detail the company's equity components like common stock and treasury stock. These financial data provide insight into AbbVie Inc.'s financial performance during the specified periods. The text also describes a partnership with Genentech to collaborate on BCL-2 inhibitors like Venclexta, profit-sharing agreements, financial reporting, goodwill, integration plans after acquiring Allergan, as well as hedging strategies, cash flow hedges, and derivatives used to manage risks related to foreign currency fluctuations and interest rates.
The text provided includes a detailed discussion and analysis of AbbVie Inc.'s financial condition and results of operations as of September 30, 2020. It covers topics such as the company overview, strategic objectives, financial results, impact of COVID-19, research and development updates, significant programs, and developments in various therapeutic areas. It also delves into net revenues by product, gross margin, selling and administrative expenses, research and development expenses, acquisitions, financing activities, cash dividends, credit risk, access to capital, credit ratings, critical accounting policies, and forward-looking statements. The text highlights financial figures, key activities, and explanatory notes regarding the company's operations and outlook.
The text states that for a discussion of the company's market risk, readers should refer to Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2019.
The text explains that the Chief Executive Officer and Chief Financial Officer of AbbVie evaluated the effectiveness of the company's disclosure controls and procedures, finding them to be effective in ensuring timely reporting to the Securities and Exchange Commission. Additionally, it mentions ongoing integration of internal controls following the acquisition of Allergan. However, it acknowledges inherent limitations in control effectiveness due to factors such as resource constraints, human error, fraud, and changing circumstances, indicating that controls can only provide reasonable, not absolute, assurance.
The text provided mentions that information about legal proceedings can be found in Note 12 of the Condensed Consolidated Financial Statements, which is referred to in the document.
The text discusses the potential impact of public health outbreaks, epidemics, or pandemics such as the COVID-19 pandemic on AbbVie's operations and financial condition. The company has implemented changes in response to COVID-19, such as remote work for employees. While the current impact on operations has not been material, the long-term effects are uncertain and dependent on the global spread of the virus and economic consequences. Ultimately, COVID-19 could have a material adverse impact on AbbVie's operations and financial condition.
The text provides information about the unregistered sales of equity securities and the use of proceeds by a company over a three-month period. The company repurchased a total of 2,861 shares at an average price of $93.50 per share, with a remaining authorization to purchase more shares under the plan. It also mentions additional shares purchased for the AbbVie Employee Stock Purchase Plan participants in July, August, and September. Additionally, it clarifies that the shares mentioned did not include those surrendered for tax obligations related to stock-based awards.
I'm here to help! Please provide me with all the parts of the text you would like me to summarize.
I'm sorry, but I am unable to summarize anything without the original text provided. Please share the text you want me to summarize.
I apologize for any confusion, but I am not able to retain information from previous messages. Could you please provide the text you would like me to summarize all at once?
The text provides detailed information regarding various exhibits attached to a document related to AbbVie Inc., specifically detailing certifications of the CEO and CFO under different regulations, along with financial statements and notes from their quarterly report for a specific period, formatted in iXBRL. Additionally, it includes the Cover Page Interactive Data File and the signature of the Executive Vice President and Chief Financial Officer of AbbVie Inc. as of November 4, 2020, in compliance with the Securities Exchange Act of 1934.
